Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients

伦瓦提尼 阿替唑单抗 医学 贝伐单抗 内科学 肝细胞癌 肿瘤科 不利影响 人口 无进展生存期 胃肠病学 癌症 无容量 化疗 索拉非尼 免疫疗法 环境卫生
作者
YEN-HAO CHEN,Yen‐Yang Chen,JING-HOUNG WANG,CHAO-HUNG HUNG
出处
期刊:Anticancer Research [Anticancer Research USA Inc.]
卷期号:43 (3): 1377-1384 被引量:2
标识
DOI:10.21873/anticanres.16286
摘要

Background/Aim: This study aimed to assess the clinical impact of lenvatinib after disease progression on atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Patients and Methods: A total of 14 patients who received lenvatinib after failure of atezolizumab plus bevacizumab and all patients were classified as having a Barcelona Clinic Liver Cancer stage C. Six patients had macrovascular invasion, and a liver occupation rate of >50% was reported in seven patients. The Kaplan–Meier method was performed to analyze the cumulative survival, while log-rank test was used to detect the differences. The dose of lenvatinib was determined based on body weight. Results: The participants’ responses to lenvatinib treatment were as follows: 21.4% achieved partial response (PR), while 35.7% had a stable disease, with a disease control rate of 57.1%. The median progression-free survival (PFS) and overall survival (OS) were 4.2 months and 8.3 months, respectively; the median PFS and OS were 6.7 months and 10.5 months in the PR group. No significant difference was observed in the median PFS and OS between patients with and without macrovascular invasion or liver occupation rate of >50%. Most of the adverse events (AEs) were categorized as grade 1-2; all patients tolerated the AEs, and no drug-related mortality was reported. Additionally, half of the population underwent subsequent therapy after progression on lenvatinib treatment. Conclusion: Lenvatinib is effective and can be safely used as second-line systemic therapy after progression on atezolizumab plus bevacizumab in patients with advanced HCC in real-world clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Orange应助li采纳,获得30
1秒前
几时有完成签到,获得积分20
1秒前
2秒前
汉堡包应助nirvana采纳,获得10
3秒前
11完成签到,获得积分10
5秒前
iconcrete完成签到,获得积分0
5秒前
无花果应助大力的镜子采纳,获得10
7秒前
小马甲应助青塘龙仔采纳,获得10
7秒前
鳗鱼邪欢完成签到 ,获得积分10
7秒前
7秒前
葡萄干发布了新的文献求助10
9秒前
9秒前
研究啥完成签到,获得积分10
10秒前
xiaonanzi1完成签到,获得积分10
11秒前
背后的文博完成签到,获得积分10
11秒前
11秒前
12秒前
汉堡包应助小张z采纳,获得10
12秒前
12秒前
LXM发布了新的文献求助10
12秒前
Lucas应助在树下采纳,获得10
14秒前
zyfqpc完成签到,获得积分10
15秒前
15秒前
正直无颜发布了新的文献求助10
16秒前
中性粒细胞1完成签到,获得积分10
17秒前
领衔发布了新的文献求助10
17秒前
17秒前
在水一方应助葡萄干采纳,获得10
18秒前
笑点低发布了新的文献求助10
18秒前
hui完成签到,获得积分10
20秒前
LXM完成签到,获得积分20
20秒前
banana完成签到,获得积分10
21秒前
小雄发布了新的文献求助10
21秒前
充电宝应助抗体小王采纳,获得10
21秒前
ciooskiwk完成签到 ,获得积分10
22秒前
大力的镜子完成签到,获得积分20
23秒前
Eva完成签到,获得积分10
23秒前
小张z发布了新的文献求助10
23秒前
23秒前
Shu完成签到 ,获得积分10
24秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3152043
求助须知:如何正确求助?哪些是违规求助? 2803339
关于积分的说明 7853343
捐赠科研通 2460804
什么是DOI,文献DOI怎么找? 1310058
科研通“疑难数据库(出版商)”最低求助积分说明 629097
版权声明 601765